Published in Infect Immun on November 01, 1998
Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog (2008) 3.02
Golgi-dependent transport of cholesterol to the Chlamydia trachomatis inclusion. Proc Natl Acad Sci U S A (2003) 2.51
The NOD/RIP2 pathway is essential for host defenses against Chlamydophila pneumoniae lung infection. PLoS Pathog (2009) 1.58
Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun (2002) 1.40
Chlamydia pneumoniae--induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect Immun (2006) 1.21
Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ (2000) 1.15
De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect Immun (1999) 1.09
NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol (2014) 1.08
Chlamydial heat shock proteins and disease pathology: new paradigms for old problems? Infect Dis Obstet Gynecol (1999) 1.04
Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J Immunol (2008) 1.02
Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect Immun (1999) 1.01
Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 1.00
PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl Recept Signal (2010) 0.98
Are reactive oxygen species always detrimental to pathogens? Antioxid Redox Signal (2013) 0.95
Microorganisms in the aetiology of atherosclerosis. J Clin Pathol (2000) 0.95
cDNA array analysis of altered gene expression in human endothelial cells in response to Chlamydia pneumoniae infection. Infect Immun (2001) 0.94
Chlamydia pneumoniae antigens, rather than viable bacteria, persist in atherosclerotic lesions. J Clin Pathol (2000) 0.91
Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro. Infect Immun (2001) 0.90
Regulation of chlamydial infection by host autophagy and vacuolar ATPase-bearing organelles. Infect Immun (2011) 0.88
The link between periodontal disease and cardiovascular disease: How far we have come in last two decades ? J Indian Soc Periodontol (2010) 0.84
GroEL1, a heat shock protein 60 of Chlamydia pneumoniae, impairs neovascularization by decreasing endothelial progenitor cell function. PLoS One (2013) 0.83
Inflammation-induced foam cell formation in chronic inflammatory disease. Immunol Cell Biol (2015) 0.82
Lack of microbial DNA in tissue specimens of patients with abdominal aortic aneurysms and positive Chlamydiales serology. Eur J Clin Microbiol Infect Dis (2007) 0.79
Amalgamation of Chlamydia pneumoniae inclusions with lipid droplets in foam cells in human atherosclerotic plaque. Virchows Arch (2008) 0.79
Chlamydia pneumoniae accelerates coronary artery disease progression in transgenic hyperlipidemia-genetic hypertension rat model. Mol Med (2003) 0.79
Atherosclerosis Induced by Chlamydophila pneumoniae: A Controversial Theory. Interdiscip Perspect Infect Dis (2013) 0.78
Identification and characterization of Chlamydia pneumoniae-specific proteins that activate tumor necrosis factor alpha production in RAW 264.7 murine macrophages. Infect Immun (2008) 0.78
The Chlamydia trachomatis CT149 protein exhibits esterase activity in vitro and catalyzes cholesteryl ester hydrolysis when expressed in HeLa cells. Microbes Infect (2012) 0.77
Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques. Heart (2005) 0.76
Effects of Porphyromonas gingivalis lipopolysaccharide on the expression of key genes involved in cholesterol metabolism in macrophages. Arch Med Sci (2016) 0.75
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
A new method for the extraction of R lipopolysaccharides. Eur J Biochem (1969) 22.41
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun (1981) 18.13
Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem (1983) 7.70
Biochemistry of endotoxins. Annu Rev Biochem (1990) 6.75
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med (1992) 5.65
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet (1997) 5.44
Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell (1976) 5.33
Monoclonal antibody against a genus-specific antigen of Chlamydia species: location of the epitope on chlamydial lipopolysaccharide. Infect Immun (1984) 4.53
Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis (1993) 4.02
Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem (1975) 3.97
C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ (1996) 3.61
The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med (1992) 3.52
Arterial foam cells with distinctive immunomorphologic and histochemical features of macrophages. Am J Pathol (1980) 3.35
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res (1978) 2.92
Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis (1995) 2.90
Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med (1996) 2.72
Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation (1993) 2.70
Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun (1996) 2.52
Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J (1992) 2.28
Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb (1993) 2.27
Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A (1995) 2.15
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis (1997) 2.06
The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun (1995) 1.94
Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood (1996) 1.93
Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation (1998) 1.86
Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis (1997) 1.82
The immunobiology and immunopathology of chlamydial infections. APMIS (1995) 1.72
Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon. N Engl J Med (1997) 1.57
Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis (1998) 1.46
Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog (1996) 1.41
Chemical, biological, and immunochemical properties of the Chlamydia psittaci lipopolysaccharide. Infect Immun (1986) 1.38
Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J Biol Chem (1985) 1.37
Stimulation of cholesteryl ester synthesis in macrophages by extracts of atherosclerotic human aortas and complexes of albumin/cholesteryl esters. Arteriosclerosis (1981) 1.37
Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis (1993) 1.23
Natural history and risk factors for early human atherogenesis. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Clin Chem (1995) 0.96
Endotoxin: possible roles in initiation and development of atherosclerosis. J Lab Clin Med (1996) 0.95
Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. Eur Heart J (1993) 0.91
Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. Arterioscler Thromb (1992) 0.83
Atherosclerosis risk factors. Pharmacol Ther (1987) 0.82
The role of inflammation in atherosclerosis. Isr J Med Sci (1996) 0.82
Modification of macrophage function and effects on atherosclerosis. Curr Opin Lipidol (1996) 0.80
The pathogenesis of atherosclerosis: a critical evaluation of the evidence. Cardiovasc Pathol (2015) 0.79
New aspects of risk factors for the development of atherosclerosis, including small low-density lipoprotein, homocyst(e)ine, and lipoprotein(a). Curr Opin Cardiol (1995) 0.78
The macrophage and its role in atherogenesis. Intern Med (1995) 0.77
Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev (1994) 4.94
Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun (1986) 4.34
Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci U S A (1993) 4.28
Parasite-specified phagocytosis of Chlamydia psittaci and Chlamydia trachomatis by L and HeLa cells. Infect Immun (1978) 4.26
Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun (1997) 3.12
Requirements for ingestion of Chlamydia psittaci by mouse fibroblasts (L cells). Infect Immun (1976) 3.11
Lymphokine-mediated inhibition of Chlamydia replication in mouse fibroblasts is neutralized by anti-gamma interferon immunoglobulin. Infect Immun (1983) 2.77
Immediate toxicity of high multiplicities of Chlamydia psittaci for mouse fibroblasts (L cells). Infect Immun (1976) 2.76
Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun (1994) 2.58
A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun (1990) 2.55
Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease. Trends Microbiol (1994) 2.54
Lymphokine-mediated microbistatic mechanisms restrict Chlamydia psittaci growth in macrophages. J Immunol (1982) 2.40
Role in vivo for gamma interferon in control of pneumonia caused by Chlamydia trachomatis in mice. Infect Immun (1988) 2.30
Effect of interferon on the growth of Chlamydia trachomatis in mouse fibroblasts (L cells). Infect Immun (1983) 2.17
Kinetics of phagocytosis of Chlamydia psittaci by mouse fibroblasts (L cells): separation of the attachment and ingestion stages. Infect Immun (1978) 1.94
Lymphokine enhances oxygen-independent activity against intracellular pathogens. J Exp Med (1983) 1.93
Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis (1999) 1.79
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65
Tumor necrosis factor alpha is a cytotoxin induced by murine Chlamydia trachomatis infection. Infect Immun (1989) 1.54
Reactivation of persistent Chlamydia trachomatis infection in cell culture. Infect Immun (1995) 1.54
IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Immunol (1993) 1.53
Inhibition of Chlamydia psittaci in oxidatively active thioglycolate-elicited macrophages: distinction between lymphokine-mediated oxygen-dependent and oxygen-independent macrophage activation. Infect Immun (1983) 1.53
Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect (1999) 1.52
Cytochalasin B does not inhibit ingestion of Chlamydia psittaci by mouse fibroblasts (L cells) and mouse peritoneal macrophages. Infect Immun (1979) 1.48
T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Clin Exp Immunol (1996) 1.48
Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis (1998) 1.46
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41
Immunoelectron-microscopic quantitation of differential levels of chlamydial proteins in a cell culture model of persistent Chlamydia trachomatis infection. Infect Immun (1994) 1.41
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33
Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun (2001) 1.28
Arrays of hemispheric surface projections on Chlamydia psittaci and Chlamydia trachomatis observed by scanning electron microscopy. J Bacteriol (1979) 1.26
Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection. Infect Immun (1999) 1.25
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20
Reactivation of chlamydial genital tract infection in mice. Infect Immun (1997) 1.17
Role for inducible nitric oxide synthase in protection from chronic Chlamydia trachomatis urogenital disease in mice and its regulation by oxygen free radicals. Infect Immun (2001) 1.15
Inducible nitric oxide synthase does not affect resolution of murine chlamydial genital tract infections or eradication of chlamydiae in primary murine cell culture. Infect Immun (1998) 1.14
Effect of interferon on a primary conjunctival epithelial cell model of trachoma. Invest Ophthalmol Vis Sci (1991) 1.11
Cytokine-mediated indoleamine 2,3-dioxygenase induction in response to Chlamydia infection in human macrophage cultures. Infect Immun (1994) 1.10
In vitro expression of factor-mediated cytotoxic activity generated during the immune response to Chlamydia in the mouse. J Immunol (1985) 1.07
Differential susceptibility of chlamydiae to exogenous fibroblast interferon. Infect Immun (1983) 1.07
Chlamydial heat shock proteins and disease pathology: new paradigms for old problems? Infect Dis Obstet Gynecol (1999) 1.04
Seroreactivity to Chlamydia trachomatis Hsp10 correlates with severity of human genital tract disease. Infect Immun (2000) 1.04
Interactions between macrophages and chlamydiae. Immunol Ser (1994) 0.99
Intracellular tryptophan pool sizes may account for differences in gamma interferon-mediated inhibition and persistence of chlamydial growth in polarized and nonpolarized cells. Infect Immun (1999) 0.99
Use of monoclonal antibodies to facilitate identification, cloning, and purification of Chlamydia trachomatis hsp10. J Clin Microbiol (1997) 0.97
Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1. Cell Immunol (1995) 0.95
Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis (2000) 0.92
Immunity to Chlamydia: comparison of human infections and murine models. Res Immunol (1997) 0.92
Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. Am J Respir Cell Mol Biol (1992) 0.90
Interferon gamma induced production of indoleamine 2,3 dioxygenase in cultured human synovial cells. J Rheumatol (1994) 0.90
Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. Microbes Infect (2001) 0.89
Role of tryptophan in gamma interferon-mediated chlamydial persistence. Ann N Y Acad Sci (1994) 0.84
Differential effects of gamma interferon on Chlamydia trachomatis growth in polarized and nonpolarized human epithelial cells in culture. Infect Immun (1998) 0.83
Chlamydial treatment failures: a persistent problem? J Eur Acad Dermatol Venereol (2001) 0.80
In vivo-activated mononuclear phagocytes and protective immunity to chlamydiae in mice. Infect Immun (1988) 0.80
Inducible nitric oxide synthase regulates production of isoprostanes in vivo during chlamydial genital infection in mice. Infect Immun (2003) 0.79
Differential modulation of lymphocyte proliferative responses and lymphokine secretion in mice during development of immunity to Chlamydia psittaci. Infect Immun (1989) 0.79
Interferons: from virus inhibitor to modulator of amino acid and lipid metabolism. J Interferon Res (1987) 0.79
Tryptophan metabolism in chronic inflammatory lung disease. J Lab Clin Med (1995) 0.78
Lymphokine stimulated macrophages inhibit intracellular Chlamydia psittaci replication by mechanisms distinct from intracellular inhibition of Toxoplasma gondii replication. Adv Exp Med Biol (1983) 0.77
The effect of intracellular Chlamydia psittaci on lysosomal enzyme activities in mouse peritoneal macrophages. Acta Pathol Microbiol Immunol Scand C (1987) 0.76
Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle. J Biol Response Mod (1990) 0.75
Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-beta Ser. J Interferon Res (1989) 0.75
The challenge of defining disease. Science (2001) 0.75